Bass/Spangenberg file new pharma IPR re-exams

Bass/Spangenberg file new pharma IPR re-exams

Hedge fund investor Kyle Bass and former IPNav CEO Erich Spangenberg have filed inter partes reviews against patents owned by Shire Pharmaceuticals and NPS Pharmaceuticals. The Irish headquartered Shire recently bought NPS in a $5.2bn deal. Its…

Unlock unlimited access to all IAM content